Baseline characteristics of patients within the whole study cohort as well as the subgroups treated with curative and noncurative intent
| . | Whole cohort (n = 75) . | Curative intent (n = 39) . | Noncurative intent (n = 36) . | P value, curative vs noncurative . |
|---|---|---|---|---|
| Male sex, n (%) | 43 (57) | 24 (62) | 19 (53) | NS |
| MPN diagnosis, n (%) | ||||
| PV/PPV-MF | 21 (28) | 10 (26) | 11 (31) | NS |
| ET/PET-MF | 23 (31) | 12 (31) | 11 (31) | NS |
| Primary myelofibrosis | 21 (28) | 12 (31) | 9 (25) | NS |
| MPN-U | 10 (13) | 5 (13) | 5 (14) | NS |
| Age at MPN diagnosis, y, median (range) | 57 (18-81) | 53 (18-80) | 64 (34-81) | .0002 |
| Age at LT, y, median (range) | 65 (36-89) | 57 (36-88) | 72 (54-89) | <.0001 |
| Latency to LT, y, median (range) | 3.9 (0.14-43) | 2.3 (0.14-33) | 5.8 (0.21-43) | NS |
| MPN JAK2 status, n (%) | n = 31 | n = 19 | n = 12 | |
| Positive | 13 (42) | 10 (53) | 3 (25) | NS |
| Negative | 18 (58) | 9 (47) | 9 (75) | |
| MPN therapies, n (%) | ||||
| 2 or less | 51 (68) | 29 (74) | 22 (61) | NS |
| 3 or more | 24 (32) | 10 (26) | 14 (39) | NS |
| Hydroxyurea | 41 (55) | 18 (46) | 23 (64) | NS |
| Anagrelide | 10 (13) | 7 (18) | 3 (8) | NS |
| Chemotherapy | 5 (7) | 0 | 5 (14) | .02 |
| ECOG at LT | n = 74 | n = 38 | n = 36 | |
| 0 or 1 (%) | 56 (76) | 35 (92) | 21 (58) | .0007 |
| ≥2 (%) | 18 (24) | 3 (8) | 15 (42) | |
| Hemoglobin, g/L | n = 73 | n = 37 | n = 36 | |
| Median (range) | 92 (51-177) | 95 (55-177) | 90.5 (51-128) | NS |
| <100, n (%) | 48 (66) | 22 (59) | 26 (72) | NS |
| ≥100, n (%) | 25 (34) | 15 (41) | 10 (28) | |
| White blood cells, ×109/L | ||||
| Median (range) | 18.5 (1-278) | 14.0 (1-213) | 28.8 (1-278) | NS |
| <20, n (%) | 38 (51) | 22 (56) | 16 (44) | NS |
| ≥20, n (%) | 37 (49) | 17 (44) | 20 (56) | |
| Platelets, ×109/L | n = 74 | n = 38 | n = 36 | |
| Median (range) | 69 (1-1800) | 87.5 (6-1800) | 42.5 (1-433) | NS |
| <100, n (%) | 48 (65) | 22 (58) | 26 (72) | NS |
| ≥100, n (%) | 26 (35) | 16 (42) | 10 (28) | |
| Blasts in PB, % | n = 73 | n = 37 | n = 36 | |
| Median (range) | 26 (0-96) | 20 (0-80) | 27.5 (1-96) | NS |
| <20%, n (%) | 25 (34) | 16 (43) | 9 (25) | NS |
| ≥20%, n (%) | 48 (66) | 21 (57) | 27 (75) | |
| Blasts in BM, % | n = 55 | n = 32 | n = 23 | |
| Median (range) | 35 (5-95) | 34.5 (5-80) | 35 (5-95) | NS |
| <50%, n (%) | 32 (58) | 20 (63) | 12 (52) | NS |
| ≥50%, n (%) | 23 (42) | 12 (37) | 11 (48) | |
| Lactate dehydrogenase, U | n = 69 | n = 35 | n = 34 | |
| Median (range) | 616 (129 - 5893) | 566 (144-5893) | 656 (129-2488) | NS |
| Albumin, g/L | n = 67 | n = 35 | n = 32 | |
| Median (range) | 36 (23-47) | 37 (28-47) | 34 (23-45) | .008 |
| Spleen status | n = 66 | n = 33 | n = 33 | |
| Splenectomy | 7 (11) | 3 (9) | 4 (12) | NS |
| Not palpable | 20 (30) | 10 (30) | 10 (30) | NS |
| Splenomegaly | 39 (59) | 20 (60) | 19 (57) | |
| Spleen <10 cm BCM* | 18 (27) | 8 (24) | 10 (30) | NS |
| Spleen ≥11 cm BCM* | 21 (32) | 12 (36) | 9 (27) | |
| Cytogenetics status, n (%) | ||||
| Cytogenetics available | 61 (81) | 32 (82) | 29 (81) | NS |
| Technical limitation | 5 (7) | 2 (3) | 3 (8) | NS |
| Not processed | 9 (12) | 5 (13) | 4 (11) | NS |
| Cytogenetic abnormalities, n (%) | n = 61 | n = 32 | n = 29 | |
| Normal | 22 (36) | 15 (47) | 7 (24) | NS |
| 1 abnormality | 15 (25) | 7 (22) | 8 (29) | NS |
| 2 abnormalities | 7 (11) | 3 (9) | 4 (14) | NS |
| 3 or more abnormalities | 17 (28) | 7 (22) | 10 (34) | NS |
| MRC classification, n (%) | n = 61 | n = 32 | n = 29 | |
| Favorable | 2 (3) | 1 (3) | 1 (3) | NS |
| Intermediate-normal | 22 (36) | 15 (47) | 7 (24) | NS |
| Intermediate-abnormal | 19 (31) | 9 (28) | 10 (34) | NS |
| Adverse | 18 (30) | 7 (22) | 11 (38) | NS |
| Abnormality patterns, n (%) | ||||
| Monosomal karyotype | 12 (20) | 4 (13) | 8 (28) | NS |
| +8 | 10 (16) | 4 (13) | 6 (21) | NS |
| del7q/-7 | 9 (15) | 3 (9) | 6 (21) | NS |
| del5q/-5 | 6 (10) | 3 (9) | 3 (10) | NS |
| del13q/-13 | 3 (5) | 0 | 3 (10) | NS |
| gain/dup 1q | 6 (10) | 3 (9) | 3 (10) | NS |
| gain/dup 9p | 3 (5) | 1 (3) | 2 (7) | NS |
| del17p/-17 | 6 (10) | 2 (6) | 4 (14) | NS |
| . | Whole cohort (n = 75) . | Curative intent (n = 39) . | Noncurative intent (n = 36) . | P value, curative vs noncurative . |
|---|---|---|---|---|
| Male sex, n (%) | 43 (57) | 24 (62) | 19 (53) | NS |
| MPN diagnosis, n (%) | ||||
| PV/PPV-MF | 21 (28) | 10 (26) | 11 (31) | NS |
| ET/PET-MF | 23 (31) | 12 (31) | 11 (31) | NS |
| Primary myelofibrosis | 21 (28) | 12 (31) | 9 (25) | NS |
| MPN-U | 10 (13) | 5 (13) | 5 (14) | NS |
| Age at MPN diagnosis, y, median (range) | 57 (18-81) | 53 (18-80) | 64 (34-81) | .0002 |
| Age at LT, y, median (range) | 65 (36-89) | 57 (36-88) | 72 (54-89) | <.0001 |
| Latency to LT, y, median (range) | 3.9 (0.14-43) | 2.3 (0.14-33) | 5.8 (0.21-43) | NS |
| MPN JAK2 status, n (%) | n = 31 | n = 19 | n = 12 | |
| Positive | 13 (42) | 10 (53) | 3 (25) | NS |
| Negative | 18 (58) | 9 (47) | 9 (75) | |
| MPN therapies, n (%) | ||||
| 2 or less | 51 (68) | 29 (74) | 22 (61) | NS |
| 3 or more | 24 (32) | 10 (26) | 14 (39) | NS |
| Hydroxyurea | 41 (55) | 18 (46) | 23 (64) | NS |
| Anagrelide | 10 (13) | 7 (18) | 3 (8) | NS |
| Chemotherapy | 5 (7) | 0 | 5 (14) | .02 |
| ECOG at LT | n = 74 | n = 38 | n = 36 | |
| 0 or 1 (%) | 56 (76) | 35 (92) | 21 (58) | .0007 |
| ≥2 (%) | 18 (24) | 3 (8) | 15 (42) | |
| Hemoglobin, g/L | n = 73 | n = 37 | n = 36 | |
| Median (range) | 92 (51-177) | 95 (55-177) | 90.5 (51-128) | NS |
| <100, n (%) | 48 (66) | 22 (59) | 26 (72) | NS |
| ≥100, n (%) | 25 (34) | 15 (41) | 10 (28) | |
| White blood cells, ×109/L | ||||
| Median (range) | 18.5 (1-278) | 14.0 (1-213) | 28.8 (1-278) | NS |
| <20, n (%) | 38 (51) | 22 (56) | 16 (44) | NS |
| ≥20, n (%) | 37 (49) | 17 (44) | 20 (56) | |
| Platelets, ×109/L | n = 74 | n = 38 | n = 36 | |
| Median (range) | 69 (1-1800) | 87.5 (6-1800) | 42.5 (1-433) | NS |
| <100, n (%) | 48 (65) | 22 (58) | 26 (72) | NS |
| ≥100, n (%) | 26 (35) | 16 (42) | 10 (28) | |
| Blasts in PB, % | n = 73 | n = 37 | n = 36 | |
| Median (range) | 26 (0-96) | 20 (0-80) | 27.5 (1-96) | NS |
| <20%, n (%) | 25 (34) | 16 (43) | 9 (25) | NS |
| ≥20%, n (%) | 48 (66) | 21 (57) | 27 (75) | |
| Blasts in BM, % | n = 55 | n = 32 | n = 23 | |
| Median (range) | 35 (5-95) | 34.5 (5-80) | 35 (5-95) | NS |
| <50%, n (%) | 32 (58) | 20 (63) | 12 (52) | NS |
| ≥50%, n (%) | 23 (42) | 12 (37) | 11 (48) | |
| Lactate dehydrogenase, U | n = 69 | n = 35 | n = 34 | |
| Median (range) | 616 (129 - 5893) | 566 (144-5893) | 656 (129-2488) | NS |
| Albumin, g/L | n = 67 | n = 35 | n = 32 | |
| Median (range) | 36 (23-47) | 37 (28-47) | 34 (23-45) | .008 |
| Spleen status | n = 66 | n = 33 | n = 33 | |
| Splenectomy | 7 (11) | 3 (9) | 4 (12) | NS |
| Not palpable | 20 (30) | 10 (30) | 10 (30) | NS |
| Splenomegaly | 39 (59) | 20 (60) | 19 (57) | |
| Spleen <10 cm BCM* | 18 (27) | 8 (24) | 10 (30) | NS |
| Spleen ≥11 cm BCM* | 21 (32) | 12 (36) | 9 (27) | |
| Cytogenetics status, n (%) | ||||
| Cytogenetics available | 61 (81) | 32 (82) | 29 (81) | NS |
| Technical limitation | 5 (7) | 2 (3) | 3 (8) | NS |
| Not processed | 9 (12) | 5 (13) | 4 (11) | NS |
| Cytogenetic abnormalities, n (%) | n = 61 | n = 32 | n = 29 | |
| Normal | 22 (36) | 15 (47) | 7 (24) | NS |
| 1 abnormality | 15 (25) | 7 (22) | 8 (29) | NS |
| 2 abnormalities | 7 (11) | 3 (9) | 4 (14) | NS |
| 3 or more abnormalities | 17 (28) | 7 (22) | 10 (34) | NS |
| MRC classification, n (%) | n = 61 | n = 32 | n = 29 | |
| Favorable | 2 (3) | 1 (3) | 1 (3) | NS |
| Intermediate-normal | 22 (36) | 15 (47) | 7 (24) | NS |
| Intermediate-abnormal | 19 (31) | 9 (28) | 10 (34) | NS |
| Adverse | 18 (30) | 7 (22) | 11 (38) | NS |
| Abnormality patterns, n (%) | ||||
| Monosomal karyotype | 12 (20) | 4 (13) | 8 (28) | NS |
| +8 | 10 (16) | 4 (13) | 6 (21) | NS |
| del7q/-7 | 9 (15) | 3 (9) | 6 (21) | NS |
| del5q/-5 | 6 (10) | 3 (9) | 3 (10) | NS |
| del13q/-13 | 3 (5) | 0 | 3 (10) | NS |
| gain/dup 1q | 6 (10) | 3 (9) | 3 (10) | NS |
| gain/dup 9p | 3 (5) | 1 (3) | 2 (7) | NS |
| del17p/-17 | 6 (10) | 2 (6) | 4 (14) | NS |
BCM = palpable below the left costal margin.
NS, not statistically significant, P value > .05; PET-MF, postessential thrombocythemia myelofibrosis; PPV-MF, postpolycythemia myelofibrosis; PV, polycythemia vera.